Compelling physiologic mechanisms have been proposed to explain a causal relationship between hyperuricemia and metabolic syndrome, chronic kidney disease, and hypertension but clinical studies have given mixed results in terms of whether intervening with hyperuricemia using urate-lowering therapy has any beneficial effects for patients with these conditions. Despite the large amount of research already put into this topic, more randomized placebo-controlled trials are needed to more firmly establish whether a cause-effect relationship exists and whether lowering uric acid levels in patients with these conditions is beneficial.
Keyphrases
- uric acid
- metabolic syndrome
- placebo controlled
- double blind
- blood pressure
- chronic kidney disease
- phase iii
- insulin resistance
- phase ii
- type diabetes
- end stage renal disease
- cardiovascular disease
- clinical trial
- cardiovascular risk factors
- study protocol
- open label
- glycemic control
- phase ii study
- squamous cell carcinoma
- randomized controlled trial
- mesenchymal stem cells
- skeletal muscle
- replacement therapy
- weight loss